These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 15329162)
1. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Turanlahti M; Boldt T; Palkama T; Antila S; Lehtonen L; Pesonen E Pediatr Crit Care Med; 2004 Sep; 5(5):457-62. PubMed ID: 15329162 [TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979 [TBL] [Abstract][Full Text] [Related]
4. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580 [TBL] [Abstract][Full Text] [Related]
6. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096 [TBL] [Abstract][Full Text] [Related]
7. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738 [TBL] [Abstract][Full Text] [Related]
9. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999 [TBL] [Abstract][Full Text] [Related]
10. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820 [TBL] [Abstract][Full Text] [Related]
12. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582 [TBL] [Abstract][Full Text] [Related]
13. The Hemodynamic Effects and Safety of Repetitive Levosimendan Infusions on Children With Dilated Cardiomyopathy. Suominen P; Mattila N; Nyblom O; Rautiainen P; Turanlahti M; Rahkonen O World J Pediatr Congenit Heart Surg; 2017 Jan; 8(1):25-31. PubMed ID: 28033083 [TBL] [Abstract][Full Text] [Related]
14. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial. Ricci Z; Garisto C; Favia I; Vitale V; Di Chiara L; Cogo PE Intensive Care Med; 2012 Jul; 38(7):1198-204. PubMed ID: 22527079 [TBL] [Abstract][Full Text] [Related]
15. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Lilleberg J; Sundberg S; Häyhä M; Akkila J; Nieminen MS Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680 [TBL] [Abstract][Full Text] [Related]
16. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Antila S; Honkanen T; Lehtonen L; Neuvonen PJ Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699 [TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Delle Karth G; Buberl A; Geppert A; Neunteufl T; Huelsmann M; Kopp C; Nikfardjam M; Berger R; Heinz G Acta Anaesthesiol Scand; 2003 Nov; 47(10):1251-6. PubMed ID: 14616323 [TBL] [Abstract][Full Text] [Related]
18. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study. Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ; Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398 [TBL] [Abstract][Full Text] [Related]
19. Effect of Preoperative Infusion of Levosimendan on Biomarkers of Myocardial Injury and Haemodynamics After Paediatric Cardiac Surgery: A Randomised Controlled Trial. Abril-Molina A; Gómez-Luque JM; Perin F; Esteban-Molina M; Ferreiro-Marzal A; Fernandez-Guerrero C; Ocete-Hita E Drugs R D; 2021 Mar; 21(1):79-89. PubMed ID: 33367965 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Jonsson EN; Antila S; McFadyen L; Lehtonen L; Karlsson MO Br J Clin Pharmacol; 2003 Jun; 55(6):544-51. PubMed ID: 12814448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]